Welcome to our dedicated page for Precipio news (Ticker: PRPO), a resource for investors and traders seeking the latest updates and insights on Precipio stock.
Precipio, Inc. (PRPO) is a NASDAQ-traded healthcare biotechnology company focused on cancer diagnostics, and its news flow reflects both its operating activities and capital markets developments. The company’s stated mission is to address cancer misdiagnoses through diagnostic products and services that improve accuracy, laboratory workflow, and patient outcomes, and many of its announcements relate to progress toward that mission.
Investors following PRPO news can expect regular updates on the company’s pathology services division and products division. Precipio issues press releases when it files quarterly reports on Form 10-Q, summarizing revenue trends in its diagnostic services and product businesses, gross margin developments, and cash flow metrics. These releases often highlight performance in pathology services and product revenues, along with management commentary on operational efficiency and financial discipline.
Company news also covers product and technology milestones. Precipio has announced developments such as its BCR::ABL1 assay and a joint study with Memorial Sloan Kettering Cancer Center, describing study results, assay performance, and impacts on patient care and laboratory workflows. Additional product-related updates may discuss customer adoption, distributor activity, and the expansion of test panels and applications in customer laboratories.
Capital structure and corporate actions are another recurring theme in PRPO news. The company has issued releases about terminating its at-the-market Sales Agreement with A.G.P./Alliance Global Partners, entering into agreements with warrant holders for cash and cashless exercises, and repaying an advance from Change Healthcare. These updates provide context on share issuance, warrant activity, cash inflows, and the company’s efforts to maintain a clean balance sheet with limited debt.
Precipio also uses news releases to communicate about shareholder update calls, cybersecurity matters, and governance-related events. For example, it has announced quarterly shareholder calls, provided details on a limited-scope unauthorized access incident in its cloud file environment, and requested shareholder participation in voting to achieve quorum at its annual meeting. For investors and analysts, the PRPO news page offers a centralized view of these operational, financial, and corporate developments over time.
Precipio (NASDAQ: PRPO) reported major balance-sheet cleanup on Jan 15, 2026. The company repaid a $1.1 million advance from Change Healthcare and now carries less than $80,000 of long-term debt (a Connecticut DECD loan amortized at $3,000/month with 3.25% interest, due May 2028). All financing warrants from the 2023 raise have been exercised; only 10,000 vendor warrants remain outstanding (strike $60, exp. Feb 2027). Management cites improved profitability and reduced financial risk for shareholders.
Precipio (NASDAQ: PRPO) will present a joint study with Memorial Sloan Kettering at the 2025 ASH meeting showing results from 895 patient samples evaluating Precipio’s BCR::ABL1 assay. The study reports superior assay performance and concordance with two leading platforms, plus improvements in patient care and laboratory workflows. The poster presentation and results discussion are scheduled for December 8, 2025, 6:00–8:00 PM at OCCC West Halls B3-B4.
Precipio (NASDAQ:PRPO) identified a single, limited unauthorized access to a specific data folder in its secure cloud file environment on Dec. 4, 2025.
Initial findings say the breach was limited to historical files in a customer service folder (operational procedures, temperature logs, vendor invoices) and did not include patient Social Security numbers, addresses, patient financial data, proprietary company data, or affect diagnostics, operations, or patient care.
The company activated incident response, engaged external cybersecurity counsel and forensic specialists, reset companywide passwords, enhanced monitoring, and reports no evidence of continued access. Precipio expects related costs to be covered by its cybersecurity insurance and currently does not anticipate material impact to operations or shareholders.
Precipio (NASDAQ: PRPO) reported Q3-2025 results on Nov 14, 2025. Revenues were $6.8M, up 30% YoY and 20% QoQ. Pathology Services revenue grew to $6.0M (+$1.0M QoQ) and Product Division sales rose to $0.72M (+16% QoQ).
Adjusted EBITDA was $469K (positive vs. $100K in Q3-2024) and operating cash flow before Change Healthcare transactions was $285K, swinging from a Q2-2025 burn of ($148K). Product gross margin fell to 30% from 44% while Pathology margin rose to 46%.
The company will hold a shareholder call on Nov 17, 2025 at 5:00 pm ET.
Precipio (NASDAQ: PRPO) will host a Q3-2025 shareholder update conference call on November 17, 2025 at 5:00 PM ET. The call will cover updates on the company’s core businesses and allow investor questions submitted in advance via email to investors@precipiodx.com. Callers can access the live call by dialing 800.717.1738 and asking for the Precipio conference call. A replay will be available about 24 hours after the call on the Investors page at https://www.precipiodx.com/investors/.
Precipio (NASDAQ:PRPO), a specialty cancer diagnostics company, has announced the termination of its At-The-Market (ATM) instrument with Alliance Global Partners (AGP). The decision reflects the company's improved financial position, marked by the elimination of negative cash flow from operations and recent increases in cash balance.
CEO Ilan Danieli emphasized that the company is now stronger and no longer needs to rely on the ATM tool for capital raises, demonstrating management's commitment to enhancing shareholder value.
Precipio (NASDAQ: PRPO) reported strong Q2-2025 financial results, with total revenues reaching $5.7M, representing a 27% YoY increase and 15% QoQ growth. The company's Pathology Services division saw an 18% QoQ increase, while Product revenues grew 23% QoQ.
Key financial metrics show significant improvement with Adjusted EBITDA of ($78K), an 87% improvement YoY, and cash used in operations decreased 71% YoY to $148K. Overall gross margins improved from 39% to 43% YoY, despite a temporary decline in Product division margins from 50% to 44% due to strategic investments in expansion.
Management expects to achieve positive cash flow and a debt-free balance sheet by year-end, following the completion of the Change Healthcare loan repayment.
Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, has scheduled its Q2-2025 shareholder update conference call for August 14th, 2025 at 5:00 PM ET. The call will provide updates on the company's core business segments.
Shareholders can access the call by dialing 800.717.1738. Questions can be submitted in advance via email to investors@precipiodx.com. A replay will be available approximately 24 hours after the call through Precipio's investor relations website.
Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, has restructured its warrant agreement with its largest warrant holder. Under the new agreement, 100,000 warrants will be exercised for cash, while the remaining 200,000 warrants will be exercised cashlessly.
The restructuring results in two key outcomes: 1) A reduction in share dilution, with total new shares decreasing from ~300,000 to ~130,000-150,000, and 2) A reduced cash inflow of $1.2 million instead of the original $3.8 million. Management will discuss this transaction during their upcoming quarterly shareholder call around August 15th, 2025.
FAQ
What is the current stock price of Precipio (PRPO)?
What is the market cap of Precipio (PRPO)?
